Vantrexa · NSCLC · Germany · Thoracic medical oncologist · captured by James Whitfield on 18 Jan 2026 · reviewed by Dr. Priya Raman on 20 Jan 2026
Marked as duplicate
Verbatim as captured; never edited
Thoracic medical oncologist at Uniklinik Köln raised pd-l1 testing turnaround during a scientific exchange. They noted that colleagues in their network share the view.
Human-approved by Dr. Priya Raman on 20 Jan 2026
PD-L1 testing turnaround: request for data reported by thoracic medical oncologist (DE).
helixor-private-llm-2026.05 · generated 18 Jan 2026, 10:00 UTC
AI summary
PD-L1 testing turnaround raised by thoracic medical oncologist; aligns with HEOR.
Source spans used by the model
Thoracic medical oncologist at Uniklinik Köln raised pd-l1 testing turnaround during a scientific exchange. They noted that colleagues in their network share the view.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Evidence gap | Evidence gap |
| Function | HEOR | HEOR |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 2 | 20% | 8.0 |
| Strategic alignment | 1 | 20% | 4.0 |
| Scientific importance | 2 | 15% | 6.0 |
| Urgency | 4 | 15% | 12.0 |
| Novelty | 5 | 10% | 10.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 3 | 5% | 3.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | Medium 53 | ||
| Time | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 07 Sept 2026, 12:37 UTC | Update | FAFatima Al-Sayed | topics | — → In progress | — | UI |
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
17 Jan 2026 · Dr. Emiko Tanaka, Uniklinik Köln · MSL James Whitfield
Insight
Reviewed 20 Jan 2026 by Dr. Priya Raman
Action
Initiative
Decision
Outcome
Closure
Shared with Clinical Development; no further action required.
Duplicate of INS-0058 — Potential safety observation: recurrent infections in OLE patient after 14 months; question on IgG monitoring frequency. Flagged for pharmacovigilance handoff.